An Open-Label, Multi-Centre, Clinical Study to Collect Information on the Clinical Use of Argatroban in Patients With Heparin Induced Thrombocytopenia (HIT) Type II Who Require Parenteral Antithrombotic Therapy.

Trial Profile

An Open-Label, Multi-Centre, Clinical Study to Collect Information on the Clinical Use of Argatroban in Patients With Heparin Induced Thrombocytopenia (HIT) Type II Who Require Parenteral Antithrombotic Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2016

At a glance

  • Drugs Argatroban (Primary)
  • Indications Embolism and thrombosis; Heparin-induced thrombocytopenia and thrombosis syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 22 Jul 2011 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 09 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Aug 2010 Planned end date changed from 1 Nov 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top